Furthermore, early cancer cells detected in bone marrow of breast cancer patients were observed to have breast cancer stem sell phenotype [27], but the frequency of CD44+/CD24-/low cells in breast cancer tissue was not correlated with clinical outcome [28]. This evidence concerns the gene CD44 and breast carcinoma.